Castle Biosciences Inc - Asset Resilience Ratio
Castle Biosciences Inc (CSTL) has an Asset Resilience Ratio of 36.47% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Castle Biosciences Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Castle Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Castle Biosciences Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Castle Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CSTL long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $204.69 Million | 36.47% |
| Total Liquid Assets | $204.69 Million | 36.47% |
Asset Resilience Insights
- Very High Liquidity: Castle Biosciences Inc maintains exceptional liquid asset reserves at 36.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Castle Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Castle Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
Annual Asset Resilience Ratio for Castle Biosciences Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Castle Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.59% | $182.78 Million | $578.56 Million | -1.05pp |
| 2024-12-31 | 32.64% | $173.42 Million | $531.24 Million | +0.82pp |
| 2023-12-31 | 31.82% | $144.26 Million | $453.34 Million | +1.49pp |
| 2022-12-31 | 30.33% | $135.68 Million | $447.33 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $462.57 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $22.40 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $9.82 Million | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more